Imatinib Mesylate (Gleevec™) for the Treatment of Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours

This clinical practice guideline reviews the use of imatinib in the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing KIT (CD117+). Recommendations are provided on dosage and schedule. Outcomes of interest include overall and progression free survival, and quality of life.